HC Wainwright Has Negative Forecast for MLTX Q1 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright dropped their Q1 2026 earnings per share estimates for MoonLake Immunotherapeutics in a research note issued to investors on Monday, May 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.98) for the quarter, down from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q2 2026 earnings at ($0.81) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.81) EPS, Q3 2027 earnings at $0.90 EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($3.06) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07).

A number of other research analysts have also recently issued reports on MLTX. The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and raised their price target for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Wolfe Research raised MoonLake Immunotherapeutics from an “underperform” rating to an “outperform” rating and upped their target price for the company from $12.00 to $24.00 in a research report on Monday, March 23rd. Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $12.00 to $40.00 in a research note on Thursday, March 19th. BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Monday, March 30th. Finally, Needham & Company LLC increased their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, MoonLake Immunotherapeutics has a consensus rating of “Hold” and a consensus price target of $23.85.

MoonLake Immunotherapeutics Stock Down 3.5%

MLTX stock opened at $18.19 on Wednesday. The stock has a market capitalization of $1.30 billion, a PE ratio of -4.70 and a beta of 1.01. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average of $17.49 and a 200 day moving average of $15.37.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the stock in a transaction dated Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total value of $62,962,500.00. Following the completion of the sale, the director owned 1,039,238 shares in the company, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Da Silva Jorge Santos sold 51,873 shares of the firm’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $18.23, for a total transaction of $945,644.79. Following the completion of the transaction, the chief executive officer directly owned 2,924,893 shares in the company, valued at $53,320,799.39. This trade represents a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,900,000 shares of company stock valued at $65,714,663 in the last ninety days. Insiders own 12.05% of the company’s stock.

Institutional Trading of MoonLake Immunotherapeutics

Several large investors have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics in the 4th quarter worth $26,000. FNY Investment Advisers LLC purchased a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth $28,000. Bank of America Corp DE boosted its position in shares of MoonLake Immunotherapeutics by 64.7% during the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after acquiring an additional 1,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after acquiring an additional 3,166 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares during the period. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.